AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications
This article was originally published in The Pink Sheet Daily
Executive Summary
An updated analysis showing no overall survival advantage for vandetanib, plus feedback from both FDA and EMEA that progression-free survival was not enough, caused AstraZeneca to withdraw the filings.
You may also be interested in...
Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs
FDA’s focus on the optimal dose for AstraZeneca’s medullary thyroid cancer treatment vandetanib could portend a harder line in ensuring that appropriate dosing for new cancer drugs is established before approval.
Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs
FDA’s focus on the optimal dose for AstraZeneca’s medullary thyroid cancer treatment vandetanib could portend a harder line in ensuring that appropriate dosing for new cancer drugs is established before approval.
FDA Committee Backs AstraZeneca's Vandetanib For Narrower Population Of Thyroid Cancer Patients
Majority of the Oncologic Drugs Advisory Committee members support use in patients with progressive or symptomatic medullary thyroid cancer, a more limited indication than that proposed by the sponsor.